Monoamine Oxidases Desensitize Intracellular Β 1 AR Signaling in Heart Failure
Ying Wang,Meimi Zhao,Qian Shi,Bing Xu,Chaoqun Zhu,Minghui Li,Vaseem Mir,Donald M. Bers,Yang K. Xiang
DOI: https://doi.org/10.1161/circresaha.121.319546
IF: 23.213
2021-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 129, No. 10Monoamine Oxidases Desensitize Intracellular β1AR Signaling in Heart Failure Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBMonoamine Oxidases Desensitize Intracellular β1AR Signaling in Heart Failure Ying Wang, Meimi Zhao, Qian Shi, Bing Xu, Chaoqun Zhu, Minghui Li, Vaseem Mir, Donald M. Bers and Yang K. Xiang Ying WangYing Wang https://orcid.org/0000-0002-8566-875X Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Meimi ZhaoMeimi Zhao Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Qian ShiQian Shi Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Bing XuBing Xu Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). VA Northern California Health Care System, Mather, CA (B.X., Y.K.X) , Chaoqun ZhuChaoqun Zhu Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Minghui LiMinghui Li Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Vaseem MirVaseem Mir Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). , Donald M. BersDonald M. Bers Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). and Yang K. XiangYang K. Xiang Correspondence to: Yang K. Xiang, PhD, Pharmacology, UC Davis, CA 95616. Email E-mail Address: [email protected] https://orcid.org/0000-0003-1786-9143 Department of Pharmacology, University of California, Davis, CA (Y.W., M.Z., Q.S., B.X., C.Z., M.L., V.M., D.M.B., Y.K.X.). VA Northern California Health Care System, Mather, CA (B.X., Y.K.X) Originally published17 Sep 2021https://doi.org/10.1161/CIRCRESAHA.121.319546Circulation Research. 2021;129:965–967is related toMeet the First AuthorsOther version(s) of this articleYou are viewing the most recent version of this article. Previous versions: September 17, 2021: Ahead of Print Meet the First Author, see p 893Desensitization of β1AR (β1 adrenergic receptor) and depressed cardiac contractility are hallmarks of heart failure (HF). Therefore, clinical drugs have been primarily aimed at rescuing β1ARs at the plasma membrane in therapy. This paradigm has been challenged by emerging evidence of functioning intracellular β1ARs at the sarcoplasmic reticulum (SR).1 The SR-β1AR regulates local PKA (protein kinase A) phosphorylation of PLB (phospholamban) and excitation-contraction coupling. Thus, enhancing β1AR signaling at the SR represents an appealing approach for effectively improving contractility in HF. We found that elevation of MAO-A (monoamine oxidase A) in HF prevents local β1AR-PKA-PLB signaling at the SR. Inhibition of MAO-A rescues local β1AR signaling, phosphorylation of PLB, and excitation-contraction-coupling in HF.We applied chronic intraperitoneal injection of β-agonist isoproterenol to induce HF. We examined SR-β1AR association with SERCA2a (sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a) using proximity ligation assay (Figure [A]). HF adult ventricular myocytes (AVMs) displayed more proximity ligation assay signals between β1AR and SERCA2a than non-HF cells, suggesting an increased β1AR association with SERCA2a in failing hearts.1 There was minimal proximity ligation assay signal between β1AR and ryanodine receptor 2 in non-HF and HF AVMs (Figure [A]). Failing hearts usually have low catecholamine contents associated with contractile dysfunction.2 Catecholamines are imported via OCT (organic cation transporter)1 and degraded by MAOs in hearts.1,2 Transcriptomic analysis of patients with dilated cardiomyopathy4 revealed significant downregulation of β1AR (ADRB1) and upregulation of MAO-A, but no change in MAO-B, OCT3, and COMT (catechol-O-methyltransferase, another catecholamine degradation enzyme; Figure [B]).Download figureDownload PowerPointFigure. Elevated monoamine oxidase A impairs intracellular β1AR signaling in failing myocytes.A, Proximity ligation assay assay of adult ventricular myocytes (AVMs) co-stained with anti-β1AR/SERCA2a (sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a) or anti-β1AR/RyR2 (ryanodine receptor 2) antibodies. Representative 3-dimensional images were randomly selected and quantified with Image J. B, Volcano plot of transcriptome mRNA from human heart failure (HF) patients with dilated cardiomyopathy relative to non-HF patients (GSE3586). Dot-plot shows the mRNA expression of MAO-A (monoamine oxidase A) from non-HF and HF patients. C, Schematic of intracellular sarcoplasmic reticulum (SR)-β1AR signaling in non-HF and HF AVMs. AVMs expressing PKA (protein kinase A) biosensors anchored on the plasma membrane and SR were pretreated with MAOi (MAO-A inhibitor; clorgyline, 5 µmol/L, 5 min) before stimulation with EPI (epinephrine, 1 µmol/L). Traces show time courses of the changes in fluorescence resonance energy transfer (FRET) YFP/CFP (yellow fluorescent protein, YFP emission intensity divide Cyan fluorescent protein, CFP emission intensity) ratio. Dot-plots show maximal increases in FRET ratio. D, Detection of PKA phosphorylation of PLB (phospholamban) at serine 16 (pS16) and LTCC (L-type Ca2+ channel) Cav1.2 at serine 1928 (pS1928) after stimulation with EPI (1 µmol/L) or dobutamine (1 µmol/L) in the presence of MAOi. E, HF AVMs were preloaded with Ca2+ indicator Fluo-4 (2 µmol/L), paced at 1 Hz, and pretreated with MAOi. Ca2+ transient (CaT) and sarcomere shortening (SS) were recorded in response to EPI, NE, or DOB. Dot-plots show maximal changes in SS, CaT amplitude (F/F0), and Ca2+ decay (Tau). Dot-plots show mean±SEM of the number of AVMs from mice (indicated). For D, P values were obtained in paired comparisons only after a significance found in a nonparametric Kruskal-Wallis test. All other data passed Shapiro-Wilk normality test. P values were obtained after 2-way ANOVA analysis followed by Tukey test (A, C, and E) or Student t test (B). AU indicates arbitrary unit; and DOB, dobutamine.We employed fluorescence resonance energy transfer-based AKAR3 (A kinase activity reporter 3)1 to assess the impacts of MAO-A on local PKA activity at the plasma membrane or SR (Figure [C]). In non-HF AVMs, epinephrine-induced robust increases in PKA activity at the plasma membrane and SR. MAOi (MAO-A inhibitor) clorgyline enhanced PKA activity only at the SR. In HF AVMs, epinephrine-induced negligible PKA activation, and MAOi selectively enhanced PKA activation at the SR. These observations imply that the upregulated MAO-A in HF limits local β1AR-PKA activation. Inhibition of MAO-A rescues intracellular β1AR-PKA signaling at the SR.Activation of SR-β1AR promotes PKA phosphorylation of PLB, a SERCA2a regulator, to enhance Ca2+ transients. MAOi selectively enhanced PKA phosphorylation of PLB in non-HF AVMs after stimulation with epinephrine but not dobutamine, a nonsubstrate for MAO (Figure [D]). In HF AVMs, MAOi enhanced epinephrine-induced increases in PKA phosphorylation of PLB at the SR but not L-type Ca2+ channel at the plasma membrane (Figure [D]).Norepinephrine, epinephrine, and dobutamine promoted little contractile response in HF AVMs. MAOi significantly rescued norepinephrine and epinephrine but not dobutamine-induced excitation-contraction (E-C) coupling (Figure [E]). Collectively, our results indicate inhibition of MAO-A restores SR-localized β1AR-PKA-PLB signaling and excitation-contraction-coupling in HF.The expression of MAO-A is increased by HF-associated pathological stresses including inflammation, aging, and reactive oxidative species. The expression of MAO-A is also regulated by hormones such as thyroid and estrogen, which affects SR calcium handling and cardiac contractility.4 Our data indicate that MAO-A inhibitors may hold promise in rescuing SR-β1AR signaling and enhancing cardiac contractility while reducing oxidative stress in HF.2Data AvailabilityThe methods, data, and materials are available upon request. C57BL/6J male mice (2–4-month-old) were randomly assigned for intraperitoneal injection of saline or ISO (30 mg/kg per day, 14 days) and blinded for data analysis. Animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health) and the protocols approved by the University of California Davis Institutional Animal Care and Use Committee (IACUC).Article InformationSources of FundingThis work was supported by NIH-HL147263 and Veteran affair BX005100 (Y.K. Xiang) and American Heart Association postdoctoral fellowships (Y. Wang and Q. Shi).DisclosuresNone.FootnotesFor Sources of Funding and Disclosures, see page 967.Correspondence to: Yang K. Xiang, PhD, Pharmacology, UC Davis, CA 95616. Email [email protected]eduReferences1. Wang Y, Shi Q, Li M, Zhao M, Reddy Gopireddy R, Teoh JP, Xu B, Zhu C, Ireton KE, Srinivasan S, et al.. Intracellular β1-Adrenergic receptors and organic cation transporter 3 mediate phospholamban phosphorylation to enhance cardiac contractility.Circ Res. 2021; 128:246–261. doi: 10.1161/CIRCRESAHA.120.317452LinkGoogle Scholar2. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, et al.. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.Circ Res. 2010; 106:193–202. doi: 10.1161/CIRCRESAHA.109.198366LinkGoogle Scholar3. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kääb S, Kreuzer E, Steinbeck G, Mansmann U, et al.. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies.J Am Coll Cardiol. 2006; 48:1610–1617. doi: 10.1016/j.jacc.2006.07.026CrossrefMedlineGoogle Scholar4. Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, Pan Y, Wickenden AD, Croteau W, Morreale de Escobar G, et al.. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction.Proc Natl Acad Sci U S A. 2006; 103:6043–6048. doi: 10.1073/pnas.0601072103CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesMeet the First AuthorsCirculation Research. 2021;129:892-894 October 29, 2021Vol 129, Issue 10Article InformationMetrics Download: 437 © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.121.319546PMID: 34530626 Originally publishedSeptember 17, 2021 Keywordsphosphorylationcatecholamineepinephrineheart failuresarcoplasmic reticulumPDF download Advertisement SubjectsBasic Science ResearchCell Signaling/Signal TransductionContractile FunctionHeart Failure